Clinical trial · no report yet · Phase 3
Trybeca-1
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC
- NCT03665441 ↗
- Completed
- ERYtech Pharma
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- eryaspase; Gemcitabine plus Abraxane; Irinotecan plus 5-FU plus leucovorin
- Arms
- Eryaspase plus Chemotherapy · Experimental
- Chemotherapy alone · Other
- Enrollment
- 512
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- ERYtech Pharma
- Start
- Sep 15, 2018
- Primary completion
- Aug 30, 2021
- Results posted
- Yes
- Registry record
- NCT03665441 · updated Oct 18, 2022
Publications
linked from the registry- Hammel P, Metges JP, Macarulla Mercade T, Garcia-Carbonero R, Bouche O, Portales F, Pazo Cid RA, Mineur L, Cubillo Gracian A, Trouilloud I, Guimbaud R, Tougeron D, Reina JJ, Feliu J, Sauri T, Fountzilas C, Lecomte T, Molin Y, Ponz-Sarvise M, Forget F, Berardi R, Van Cutsem E, Gelsomino F, Tournigand C, Bockorny B, Bachet JB, Marin Vera M, Cuyle PJ, Wasan H, Noel M, Van Laethem JL, Kay R, Youssoufian H, El-Hariry I, Hidalgo M. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma. J Clin Oncol. 2025 Dec 10;43(35):3714-3727. doi: 10.1200/JCO-25-00872. Epub 2025 Nov 4. PubMed 41187298